Business
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023
Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023 SALT
About this update from Lipocine Inc.
[{"type":"text","content":"Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023\nSALT LAKE CITY, June 7, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary technology platform to develop differentiated products, today announced that it will present posters on LPCN 1148 and LPCN 1144 at the forthcoming European Association for the Study of the Liver (EASL) Congress 2023, to take place in Vienna, Austria, June 21 – 24, 2023.\n\n \n \n \n \n \n \n\n \nA multimodal treatment candidate for sarcopenia in men with decompensated cirrhosis: a randomized, placebo-controlled trial evaluating LPCN 1148 \nLead author and presenter: Dr. Benjamin J. Bruno, Senior Director of Clinical Development at Lipocine Session: Cirrhosis and its complications: Other clinical complications except ACLF and critical illness Date and Time: Wednesday, 21 June, 9:00 am CEST Room: Poster Area Poster ID: WED-358\nEfficacy and safety of LPCN 1144 in hypogonadal and eugonadal subjects for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis\nLead author and presenter: Dr. Benjamin J. Bruno, Senior Director of Clinical Development at Lipocine Session: NAFLD: Therapies Date and Time: Friday, 23 June, 9:00 am CEST Room: Poster Area Poster ID: FRI-466 Selected for Poster Tour presentation\nDr. Bruno will give a live presentation of this poster followed by a Q&A session during the Poster Tour on June 24th at 15:30-16:15 at the Metabolism, Alcohol, and Toxicity Track hub.\nThe posters will be available on Lipocine's corporate website following the meeting.\nAbout LPCN 1148\nLPCN 1148 is a novel androgen receptor agonist prodrug for oral administration with compelling multi modal action to improve liver and muscle function, resulting in improved quality of life while awaiting liver transplant, decreased hospital admissions, and prevention or reduction in occurrence and recurrence of decompensation events.\nAbout LPCN 1144\nLPCN 1144, a novel androgen receptor agonist prodrug for oral administration, is being developed as a treatment for pre-cirrhotic non-alcoholic steatohepatitis (NASH) and recently completed a Phase 2 paired biopsy clinical study (LiFT or Liver Fat interv...